HD-OPM Archive

Keto, low-carb and lean mass hyper-responders

What ketogenic and very low-carb diets do to LDL and arterial plaque, what the KETO-CTA study in lean mass hyper-responders did and did not show, and how the group's admins suggest keto fans keep an eye on their hearts.

19 min read58 group posts cited27 studies discussed4 chartsEvidence through Oct 2026AI Summary of posts by Louis Nervegna and Gokhan Can
Key takeaways
  • Many people on strict keto see LDL rise, and a minority of very lean people see extreme rises (the "lean mass hyper-responder" or LMHR pattern, with LDL often cited above 190 mg/dL and sometimes far higher).
  • KETO-CTA followed 100 LMHRs (average LDL about 254 mg/dL) for one year with CT angiography; total plaque volume rose about 0.8% on average, and 2.4% in those who started with a calcium score above 100.
  • The study had no control group, its primary outcome was missing from the paper, and the original Cleerly plaque numbers were later re-analysed with other software (about 5.5 mm3 rise instead of 18.8 mm3), after which the paper was retracted.
  • Even on the more favorable re-analysis, the admins argue progression was no better than in people eating a standard Western diet, and far from the regression seen with a DASH diet plus statins in DISCO-CT.
  • Keto has real short-term upsides in weight, liver fat and glucose, but the edge over other diets fades when calories are matched or follow-up extends to 12 to 24 months.
  • The group's advice for anyone on keto: do not ignore LDL and ApoB, consider a CT scan if you have been on keto with high LDL, and discuss treatment with your doctor.
In this summary
  1. Key terms in plain language
  2. Why LDL rises on keto, and who is most affected
  3. What KETO-CTA was and what it found
  4. How the plaque growth compares with other groups
  5. The controversy: primary outcome, re-analysis and retraction
  6. What else the group's posts say about keto
  7. Nuances and common misconceptions
  8. What this means for you
  9. Frequently asked questions
  10. The evidence behind this summary

The short answer is that a ketogenic or very low-carb diet often raises LDL cholesterol, sometimes dramatically, and that being lean and metabolically healthy does not appear to cancel out the effect of that LDL on the arteries. The best direct test of this idea so far is the KETO-CTA study of "lean mass hyper-responders", which found measurable plaque growth over one year in people who already had plaque.12 The study was also heavily criticized, partly re-analysed and eventually retracted, so the details matter.34

That does not make every low-carb diet harmful. The group's posts describe real short-term benefits for weight, liver fat and blood sugar, and show that the answer depends on what you eat and how high your LDL goes.56 This article covers the numbers, where the evidence is solid or shaky, and what the admins suggest doing.

100lean, metabolically healthy keto dieters with LDL around 254 mg/dL, scanned a year apart in KETO-CTA1
18.8 → 5.5 mm³median one-year rise in soft plaque: original software versus the blinded re-analysis3
2.18adjusted hazard ratio for major cardiac events in low-carb high-fat eaters versus a standard diet (observational)7
67% vs 45%drop in liver fat on keto versus Mediterranean or plant-forward diets at equal weight loss5

Key terms in plain language

  • Ketogenic (keto) diet: a very low-carbohydrate, high-fat diet that pushes the body to burn fat and make ketones such as beta-hydroxybutyrate (BHB).11
  • LDL-C and ApoB: two ways of measuring the cholesterol-carrying particles that enter artery walls. Nick Norwitz is paraphrased as saying ApoB is causal for atherosclerosis and necessary for it, though not necessarily sufficient.12
  • Lean mass hyper-responder (LMHR): a lean, fit, metabolically healthy person (low triglycerides, high HDL) whose LDL-C rises very high on keto, often 190 mg/dL or more.3
  • CAC and CTA: a coronary artery calcium (CAC) score measures calcified plaque. A CT angiogram (CTA) also shows soft, non-calcified plaque, which is the type KETO-CTA was designed to track.1314
  • NCPV and PAV: non-calcified plaque volume (NCPV, in mm3) is the amount of soft plaque. Percent atheroma volume (PAV) is the share of the scanned vessel volume occupied by plaque, soft plus hard.1314

Why LDL rises on keto, and who is most affected

Population data show that low-carbohydrate high-fat (LCHF) eating tends to raise LDL. A cohort analysis in JACC: Advances found significantly higher LDL-C and ApoB in LCHF eaters than in people on a standard diet. Severe hypercholesterolemia (LDL-C above 5 mmol/L) was seen in 11.1% of LCHF versus 6.2% of standard-diet participants, and major adverse cardiovascular events over 11.8 years occurred in 9.8% versus 4.3% (adjusted hazard ratio 2.18, 95% CI 1.39 to 3.43). Those with a high LDL polygenic risk score had the highest LDL on LCHF.7 This is an observational association, so it cannot prove the diet caused the events.

Low-carb high-fat eaters had more high LDL and more heart eventsShare of participants, low-carb high-fat (LCHF) versus standard diet, cohort analysis in JACC: Advances, 11.8 years
LCHF dietStandard diet
Severe hypercholesterolemia (LDL-C above 5 mmol/L)11.1%6.2%
Major adverse cardiovascular events9.8%4.3%
Observational. Adjusted hazard ratio for major events 2.18 (95% CI 1.39–3.43). Source: 7
Show data
LCHF dietStandard diet
Severe hypercholesterolemia (LDL-C above 5 mmol/L)11.1%6.2%
Major adverse cardiovascular events9.8%4.3%

For the extreme end, Louis Nervegna offers a hypothesis rather than a proven mechanism. In his view, a very lean person with almost no body fat who also removes carbohydrate and stays in ketosis can trick the body into acting as if it is starving. Circulating LDL then rises to deliver fat as fuel, leptin falls (which reduces LDL receptors and slows clearance), and thyroid and sex hormones fall. He links a 1999 Journal of Nutrition study in which fasting raised total cholesterol, LDL-C and ApoB in healthy non-obese people. He says it is more common with ApoE4 and when keto is combined with fasting and intense exercise.1516

Louis mentions LDL values of 500 or even 1,000 mg/dL in LMHRs, while KETO-CTA participants averaged about 254 mg/dL (a comparison chart reproduced in the group lists 237 mg/dL).11517

Not everyone on a low-carb diet responds the same way. Louis points out that lipid expert Tom Dayspring has followed a very low-carbohydrate (not keto) diet for years while keeping his LDL very low.18 Gokhan Can, who did keto on and off for about seven years, says he did not get sky-high LDL, still controls it with low-dose rosuvastatin, and avoids carnivore eating.19 A keto practitioner reshared by Gokhan reported that 15 years of keto lowered blood pressure, triglycerides, HbA1c, insulin and hsCRP but raised LDL and ApoB until he added ezetimibe.20

What KETO-CTA was and what it found

KETO-CTA was a one-year prospective cohort study of 100 lean, metabolically healthy people on keto with very high LDL (average about 254 mg/dL). They were active and health-conscious, most took "heart healthy" supplements, many fasted intermittently, and none had a diagnosis of heart disease.12 It was published in JACC: Advances in 2025 under the title "Plaque Begets Plaque, ApoB Does Not".14

Louis summarizes the headline results as follows:

  • Total plaque volume rose by 0.8% on average after one year.1
  • In people with a baseline CAC above 100, it rose by 2.4%, about three times the study average.12
  • In people with a 10-year risk above 5% on the standard AHA calculator, it rose by 1.4%, about twice the average.1
  • People with no plaque at baseline were unlikely to develop it within a year, no matter how high their LDL.12
  • Baseline plaque was strongly associated with progression, while ApoB was not, which is the basis of the paper's "plaque begets plaque" title.1
  • In the individual-level figure, no participant showed regression of non-calcified plaque, and those who started with the most plaque progressed the most.213
Panels from the KETO-CTA paper shared in the group: one-year change in non-calcified plaque volume plotted against change in ApoB, baseline ApoB and baseline calcium score. The fitted line is nearly flat for ApoB but rises steeply with baseline CAC, the basis of the "plaque begets plaque" title.
Panels from the KETO-CTA paper shared in the group: one-year change in non-calcified plaque volume plotted against change in ApoB, baseline ApoB and baseline calcium score. The fitted line is nearly flat for ApoB but rises steeply with baseline CAC, the basis of the "plaque begets plaque" title.13

A table from the paper, as Louis reads it, shows PAV rising from 0.6% to 1.1% in people with CAC of zero, from 1.6% to 2.4% for the average participant, from 4.5% to 5.9% for the above-5%-risk group and from 9.6% to 12% for CAC above 100.14 Louis extrapolated those rates: people with CAC above 100 would cross the "severe plaque" line (PAV above 15%) in about 3 years, the average participant in about 17. He cautioned these straight-line projections are probably upper bounds.22

Plaque grew in every KETO-CTA subgroup, most where it already existedPercent atheroma volume (share of the vessel occupied by plaque) at baseline and after one year, as Louis reads the paper's table
BaselineAfter one year
Calcium score zero0.6%1.1%
Average participant1.6%2.4%
10-year risk above 5%4.5%5.9%
Calcium score above 1009.6%12%
No control group; the paper was later retracted. "After one year" values are Louis's reading of baseline plus the reported yearly change. Source: 14
Show data
BaselineAfter one year
Calcium score zero0.6%1.1%
Average participant1.6%2.4%
10-year risk above 5%4.5%5.9%
Calcium score above 1009.6%12%

Gokhan makes a similar point from experience: group members who looked and felt excellent after years of keto or carnivore eating nevertheless had very early heart attacks, including a 95% blockage of the left anterior descending artery ("widowmaker") and a widowmaker heart attack at age 35.23 These are anecdotes, not controlled evidence.

How the plaque growth compares with other groups

The study had no control group, so the admins compared its numbers with other CT angiography cohorts. These cross-study comparisons are not randomized, a limitation critics raise.21

Nature-CT (standard diet, no medication). Louis highlights this as the closest comparison: a Budoff-led study from the same institute, with the same scanners and Cleerly software, a mean age of about 55, no diabetes and no lipid-lowering drugs. Over one year, NCPV rose 18.8 mm3 in the LMHR group versus 4.9 mm3 in Nature-CT, about 3.8 times faster. Budoff reportedly agreed it was a good comparison and planned a paper on it.1724 Later Louis acknowledged that Nature-CT's baseline plaque was a little lower (median 27.5 versus 44 mm3) but argued the difference was too small to invalidate the comparison.8

PARADIGM (serial CTA cohort). Quoting an analysis, Louis reports PARADIGM progression of about 3.2 mm3 per year in people without metabolic syndrome and about 5.6 mm3 per year with it, and only about 0.5 mm3 per year in properly statin-treated patients.2526 Nicola Guess made a similar estimate: about 13 mm3 over three years in PARADIGM's high-risk patients against about 20 mm3 in one year for the keto group, reading values off the paper's figure.27

The paper's supplemental table comparing yearly change in percent atheroma volume in KETO-CTA (overall and by subgroup) with other CT cohorts, including PARADIGM. Values are medians with 25th–75th percentiles.
The paper's supplemental table comparing yearly change in percent atheroma volume in KETO-CTA (overall and by subgroup) with other CT cohorts, including PARADIGM. Values are medians with 25th–75th percentiles.14

Diabetes, SMARTool and PCSK9 comparisons. The quoted analysis places 18.8 mm3 per year near the roughly 17.4 mm3 per year seen in type 2 diabetes in a Budoff cohort, and nearly three times the 6.4 mm3 per year of SMARTool high-risk patients not on statins (1.0 mm3 per year on statins).26 In a separate Budoff study, higher-risk patients (53% hypertensive, 21% diabetic) whose LDL was lowered to about 30 mg/dL with the PCSK9 inhibitor Repatha mostly showed major plaque regression, while all the keto participants progressed or stayed neutral.13

DISCO-CT (statins plus DASH diet). In DISCO-CT, patients with non-obstructive coronary disease had plaque regression. The group cites a mean NCPV change of -21.3 mm3 with optimal medical therapy alone and -51.3 mm3 with added dietitian-led DASH diet advice, and elsewhere Louis plots -39.5 mm3 for DASH plus statins.828 Louis points out that DISCO-CT participants had nearly ten times more baseline plaque, yet regressed.8 The group describes DASH as very similar to a traditional Mediterranean diet.29

Colchicine. In another Budoff-led CT trial, 0.5 mg of colchicine daily reduced PAV by over 1% in a year versus placebo, which Louis contrasts with the 0.8% rise on keto. Budoff called it a small study.30

The controversy: primary outcome, re-analysis and retraction

The KETO-CTA paper was criticized almost from the day it appeared. The main concerns, as the group's posts describe them:

  • Missing primary outcome. The registered primary outcome was the percent change in non-calcified plaque volume, but the paper's abstract and main text did not report it.2127 A letter to JACC says the lead author later shared a median rise of 18.8 mm3, roughly 43% above baseline.28 Gokhan has described it as a 50% rise in the median participant, which is his own rounding of the posted figure.31 People who reconstructed the paper's scatter plots reported a mean rise of 32.3 mm3, though that was a community reconstruction and not an official correction.32
  • No control group, short follow-up and historical controls. Michael Albert notes that one year is brief compared with the 3 to 6 years of most plaque imaging studies and that cross-study comparisons ignore differences in baseline risk and imaging methods.21
  • The "ApoB does not matter" claim. John Mandrola's Medscape review is described as concluding that the data are nowhere near supporting the authors' claim that LDL is unrelated to atherosclerosis.3334 Louis shares an illustration suggesting that picking a small group from an extreme range of ApoB can make a real association look absent, a statistical explanation of why no ApoB link was seen.35
  • Study design. Before results came out, Louis paraphrased Spencer Nadolsky, who helped write the original LMHR protocol, saying that enrolling only extremely healthy people, with no atherosclerosis, made detectable progression within a year unlikely, and that people with existing atherosclerosis would have been more informative.36
The simulation Louis shared: in a general population ApoB and plaque change correlate clearly, but a small sample drawn only from the extreme high end of ApoB, as in KETO-CTA, shows almost no slope. A missing statistical association is not proof of no effect.
The simulation Louis shared: in a general population ApoB and plaque change correlate clearly, but a small sample drawn only from the extreme high end of ApoB, as in KETO-CTA, shows almost no slope. A missing statistical association is not proof of no effect.35

Budoff, the senior author, reportedly said in a video that the paper had major problems and that he was rewriting it, per Louis's summary of that video.3738 Louis at first argued the paper should stay published because the dataset was public and valuable and because the criticism targeted the write-up more than the methodology.33 In January 2026 JACC: Advances issued an Expression of Concern, announcing a confidential review of data integrity concerns under COPE guidelines. Louis notes that no evidence of wrongdoing had been presented and that some authors appear to have requested the review.4

By October 2026 Louis reports that the paper was retracted over concerns about the quality, blinding and reliability of the Cleerly automated plaque software. The investigators re-analysed the 200 scans with HeartFlow and QAngio. The fully blinded HeartFlow analysis gave a median NCPV rise of 5.5 mm3 and QAngio 5.6 mm3, compared with Cleerly's 18.8 mm3.3 Louis argues that this still matches the roughly 4.9 mm3 seen in Nature-CT's standard-diet group, and is as bad as people with untreated metabolic syndrome in PARADIGM (5.6 mm3 per year). He describes the change as moving from "horrible" to "just plain bad", while noting the re-analysis has not been peer reviewed.825

Revised keto plaque growth still matched untreated cohortsChange in non-calcified plaque volume, mm³ per year, as quoted in the group's posts
KETO-CTA, original Cleerly analysis18.8
Type 2 diabetes (Budoff cohort)17.4
SMARTool high-risk, no statins6.4
PARADIGM, with metabolic syndrome5.6
KETO-CTA, blinded HeartFlow re-analysis5.5
Nature-CT, standard diet, no medication4.9
PARADIGM, without metabolic syndrome3.2
SMARTool, on statins1.0
PARADIGM, properly statin-treated0.5
Cross-study comparisons with different populations and methods, not randomized. The original 18.8 figure came from the retracted paper; the re-analysis is not peer reviewed. DISCO-CT (statins plus DASH diet) showed regression; see the text. Source: 3242526
Show data
mm³ per year
KETO-CTA, original Cleerly analysis18.8
Type 2 diabetes (Budoff cohort)17.4
SMARTool high-risk, no statins6.4
PARADIGM, with metabolic syndrome5.6
KETO-CTA, blinded HeartFlow re-analysis5.5
Nature-CT, standard diet, no medication4.9
PARADIGM, without metabolic syndrome3.2
SMARTool, on statins1.0
PARADIGM, properly statin-treated0.5

A fair reading is that the original large numbers (18.8 and 32.3 mm3) are now in doubt, the lower re-analysed numbers still show a rise in plaque in lean, healthy people, and there is still no control group. Gokhan also pointed readers to three detailed critiques (Kevin Klatt, Alex Leaf and Nicola Guess).32539 A quoted newsletter line he shared is blunter: people with sky-high LDL on low-carb diets should seriously consider lipid-lowering treatment.40

What else the group's posts say about keto

Possible benefits

Gokhan, who does keto for 3 to 12 months at a time, lists anti-inflammatory effects of BHB, appetite regulation and better insulin sensitivity, triglycerides and blood pressure.11 Stanford researchers described BHB-amino acids, new keto metabolites that suppress appetite, though the heart relevance is indirect.41 An 18-patient glioblastoma study reported 67% versus 8% three-year survival on keto, but Louis calls it tiny and the evidence mixed.42

A 2026 Cell Metabolism trial (Petersen et al.) fed 42 adults with obesity, prediabetes and fatty liver all their meals on keto (4% carbohydrate), Mediterranean (50%) or very-low-fat plant-forward (70%) diets until about 10% weight loss. All diets improved muscle insulin sensitivity and body composition, but liver fat fell 67% on keto versus 45% on the other two, and about half the keto group no longer met prediabetes criteria versus 29% on Mediterranean and 7% on plant-forward.543 Louis calls it a small study and wonders whether a Mediterranean-style keto diet would do even better.5

At equal weight loss, keto cut the most liver fatChange in liver fat after about 10% weight loss on fully provided diets, 42 adults with obesity, prediabetes and fatty liver (Cell Metabolism, 2026)
Ketogenic (4% carbohydrate)−67%
Mediterranean (50% carbohydrate)−45%
Very-low-fat plant-forward (70% carbohydrate)−45%
Small trial; all three diets improved insulin sensitivity and body composition. Source: 543
Show data
Value
Ketogenic (4% carbohydrate)−67%
Mediterranean (50% carbohydrate)−45%
Very-low-fat plant-forward (70% carbohydrate)−45%

Weight loss and diabetes are less clear over time

  • Louis notes that when calories are strictly matched in metabolic ward studies by Kevin Hall, low-carb diets did not produce more fat loss than normal-carb diets; appetite control is probably the main reason they work.44
  • Gokhan cites a 2021 BMJ meta-analysis (23 trials) in which benefits at 6 months diminished by 12 months, and a 2020 meta-analysis (37 trials, 3,301 patients) in which the HbA1c advantage disappeared by 12 months and slightly reversed by 24 months. A 2-year trial comparing about 14% versus about 53% carbohydrate found identical weight loss (about 6.7 kg). His summary is that the benefit comes from adherence.45
  • Louis stresses that a lower A1C on keto is not proof that diabetes has been cured. In his view only passing an oral glucose tolerance test shows that, and he describes liver and pancreas fat as the key.46 He also says very low-carb eaters rarely reach an A1C below 5 because of "physiological insulin resistance", the muscles sparing glucose, which is his own physiological reasoning rather than a trial result.47
  • A 30-year Harvard cohort of over 200,000 people, as summarized in a video Gokhan shares, found that low-carb diets heavy in animal protein, saturated fat and refined carbohydrate such as white potatoes were linked to higher type 2 diabetes risk, while plant-based low-carb patterns (nuts, avocado, whole grains) were linked to lower risk.6

Other cautions raised in the group

  • Methylglyoxal: a 2005 study of people on the Atkins diet found methylglyoxal, a glycation precursor, rose 1.67-fold by 14 to 28 days (2.12-fold in those in ketosis). Louis cautions that this measured markers, not outcomes.48
  • Thyroid: Louis says prolonged very low-carb eating can lower T3 and T4 while TSH looks normal or low, and suggests gradually adding whole-food carbohydrates if full hypothyroidism is suspected. This is his mechanistic opinion without cited studies.4950
  • Long-term unknowns: a long-term mouse study found keto protected against weight gain at first but later produced high cholesterol, fatty liver and impaired insulin secretion.51 Louis also argues that no long-lived population ate a carbohydrate-free diet, so the long-term heart effects are unknown.52
  • Evidence quality: Louis calls an NHANES cross-sectional study suggesting keto might lower all-cause mortality hypothesis-generating at best.53
  • A case report: a Circulation abstract described one LMHR patient whose coronary disease progressed rapidly after stopping a statin and starting keto; the authors advise caution for people with known coronary disease.54

Nuances and common misconceptions

  • "If I look and feel great, my arteries must be fine." Gokhan's view is that appearance and energy do not rule out silent plaque, and that LDL and ApoB are the markers to follow.23
  • "Good metabolic health protects against high LDL." Louis argues KETO-CTA tested this and found no protection in people with existing plaque, though people with zero plaque were unlikely to develop it within a year.155 Norwitz, as paraphrased, thinks the LMHR phenotype as a whole may carry different absolute risk and that the absolute benefit of lowering ApoB in LMHR is unknown.12
  • "The study proved keto is deadly." It measured plaque on scans, not heart attacks, and its largest numbers have since been revised.13
  • "The study proved keto is safe." It did not. Nadolsky's concern, as relayed by Louis, is that one year in extremely healthy people could not show harm even if it exists.36
  • "Keto means carnivore." Gokhan suggests a nut-, fish- and olive-oil-heavy keto rather than a saturated-fat-heavy one.9 Louis shares a strict carnivore advocate's report of worsening cardiovascular health after 15 years, as anecdote not controlled evidence.56

What this means for you

These are points raised in the group, not individual medical advice. The admins recommend discussing them with your own doctor.

  • Check your numbers on keto. Gokhan's advice is never to ignore LDL, and to consider cutting back on saturated fat in favor of nuts, fish and olive oil.9
  • Consider imaging if you have been on keto with high LDL. Budoff, the study's principal investigator, recommends CT angiograms for his keto patients, and reportedly recommends a statin, low-dose aspirin and tight blood pressure control for those with significant plaque. He says the statin is aimed at the plaque, since statins slow progression even at low LDL.10 One keto practitioner chose a radiation-free carotid intima-media thickness test and still plans a CCTA.20
  • Zero plaque is the best-case scenario. In KETO-CTA, people with no plaque at baseline were unlikely to develop it within a year, but the study could not say what happens over longer periods.114
  • If you do low-carb, keep some carbohydrate and quality. Louis suggests including low-glycemic carbohydrates from non-starchy vegetables, legumes, berries, nuts, seeds and fermented dairy.52 Gokhan's own "Mediterranean plus low-carb" menu leans on vegetables, fish, eggs and nuts.57
  • Watch for thyroid changes if you combine strict low-carb with heavy fasting or exercise.4950
  • Treat single studies cautiously. The KETO-CTA saga shows how a headline number can change after re-analysis, and Louis has criticized influencers who he says misrepresent it.358

Frequently asked questions

Did KETO-CTA prove keto causes plaque?

No. It was a one-year cohort of 100 people with no control group, so it cannot isolate the effect of keto.121 What it does show is that lean, metabolically healthy people with very high LDL, especially those with baseline plaque, still had plaque growth.214 The original numbers were later questioned, and the paper retracted.3

Why was the KETO-CTA paper retracted?

Per Louis, the retraction followed concerns about the quality, blinding and reliability of the Cleerly plaque-analysis software.3 A January 2026 Expression of Concern had said data integrity concerns were under confidential review, and Louis notes no evidence of wrongdoing had been presented at that point.4

Is my LDL on keto a problem if my other numbers look great?

The admins suggest not assuming so. Louis argues good metabolic health did not protect people with existing plaque in KETO-CTA, while others (such as Norwitz as paraphrased) say the absolute risk in LMHRs is uncertain.1255 Because this is unresolved, the practical advice is to measure LDL and ApoB, consider imaging, and discuss it with a doctor.1023

Is keto better than a Mediterranean diet?

For liver fat in a small, tightly controlled trial, keto did better than both Mediterranean and low-fat plant-forward diets, though the Mediterranean diet also helped.543 For plaque, the admins point to DISCO-CT, where a DASH diet plus statins produced regression.829 When calories are matched, fat loss is similar.44

Do all very low-carb diets raise LDL?

Not in everyone. Dayspring's very low-carb diet comes with a very low LDL, and the LCHF cohort found the highest LDL in people with a high LDL polygenic risk score.718

The evidence behind this summary27 studies · 2 meta-analyses · 6 trials · 9 observational

The 58 group posts cited above discuss 27 studies and sources. Their mix of study designs shows how much rests on randomized trials and meta-analyses, which can show cause and effect, and how much on observational, lab or animal work, which mostly cannot.

Meta-analyses 2Randomized trials 6Observational studies 9Reviews & guidelines 1Animal & lab studies 1Other sources 8

Strongest evidence discussed

All 27 studies and sources
Sources from the group (58)
  1. Keto-CTA (LMHR): very high LDL keto dieters with plaque kept progressing despite lean Louis Nervegna · Apr 07, 2025 · Facebook
  2. Keto-CTA: LMHR group's 0.8% plaque volume rise exceeded that of typical Western cohorts Louis Nervegna · Apr 08, 2025 · Facebook
  3. Keto-CTA vs DISCO-CT: plaque progression on keto in LMHR versus DASH diet plus statins Louis Nervegna · Oct 25, 2026 · Facebook
  4. JACC issues Expression of Concern on KETO-CTA 'Plaque Begets Plaque' paper Louis Nervegna · Jan 30, 2026 · Facebook
  5. Keto cut liver fat 67% vs 45% on Mediterranean or plant-forward diets in a small RCT Louis Nervegna · Aug 31, 2026 · Facebook
  6. Harvard cohort: unhealthy low-carb diets raise diabetes risk, plant-based ones lower it Gokhan Can · Nov 30, 2025 · Facebook
  7. Low-carb high-fat diet linked to higher LDL-C, ApoB and 2.18-fold MACE risk at 11.8 years Louis Nervegna · May 04, 2024 · Facebook
  8. Keto-CTA reanalysis: plaque progression still no better than the standard American diet Louis Nervegna · Sep 06, 2025 · Facebook
  9. Opinion: keto is not heart healthy if LDL rises; never ignore LDL Gokhan Can · Apr 13, 2025 · Facebook
  10. Budoff recommends statins, aspirin and BP control for keto dieters with CT-detected plaque Louis Nervegna · Apr 14, 2025 · Facebook
  11. A balanced look at the ketogenic diet: anti-inflammatory potential and caveats Gokhan Can · Nov 26, 2023 · Facebook
  12. Nick Norwitz's eight statements on ApoB, keto, LMHR and the J-shaped curve Louis Nervegna · Jul 23, 2024 · Facebook
  13. Keto-CTA plaque progression vs plaque regression on Repatha in Budoff's other study Louis Nervegna · Apr 09, 2025 · Facebook
  14. Keto-CTA (LMHR): plaque volume rose 25-100% in one year across CAC and risk subgroups Louis Nervegna · Apr 09, 2025 · Facebook
  15. Why the LMHR phenotype happens: starvation-like physiology in lean keto dieters Louis Nervegna · Jan 25, 2024 · Facebook
  16. Why LMHR happens: starvation-like physiology in very lean people on keto raises LDL Louis Nervegna · Jul 23, 2024 · Facebook
  17. Keto-CTA: high LDL with good metabolic health still saw 3.8x faster plaque progression Louis Nervegna · Aug 21, 2025 · Facebook
  18. Tom Dayspring on high LDL-C on keto diets; his own very low-carb diet keeps LDL low Louis Nervegna · Dec 18, 2024 · Facebook
  19. KETO-CTA compared high-LDL to very-high-LDL keto dieters with no low-LDL control group Gokhan Can · Apr 15, 2025 · Facebook
  20. Staying keto while still tracking ApoB and plaque markers (shared from Dominic D'Agostino) Gokhan Can · Aug 30, 2025 · Facebook
  21. KETO-CTA's preregistered primary outcome was missing from the paper, says Dr Albert Gokhan Can · Apr 12, 2025 · Facebook
  22. Keto-CTA extrapolation: LMHRs with CAC over 100 hit 'severe plaque' (PAV >15%) in ~3 years Louis Nervegna · Apr 14, 2025 · Facebook
  23. Looking healthy on keto or carnivore does not rule out silent plaque, citing KETO-CTA Gokhan Can · May 29, 2025 · Facebook
  24. Keto-CTA hyper-responders progressed soft plaque 3.8x faster than Nature-CT controls Louis Nervegna · Apr 18, 2025 · Facebook
  25. After reanalysis, Keto-CTA plaque growth still matches untreated metabolic syndrome Louis Nervegna · Mar 02, 2026 · Facebook
  26. Keto-CTA plaque growth matched diabetics' and far exceeded high-risk statin-treated groups Louis Nervegna · Apr 16, 2025 · Facebook
  27. Nicola Guess: Keto-CTA plaque rose ~20 mm3 in 1 year vs ~13 mm3 over 3 years in PARADIGM Louis Nervegna · Apr 12, 2025 · Facebook
  28. Letter to JACC: Keto-CTA omitted pre-specified outcome, a 43% rise in non-calcified plaque Louis Nervegna · Apr 21, 2025 · Facebook
  29. DISCO-CT diet-plus-medication group showed plaque reversal, unlike progression in Keto-CTA Louis Nervegna · Jul 17, 2025 · Facebook
  30. Colchicine 0.5 mg cut plaque volume by over 1% in one year on CT angiography (Budoff) Louis Nervegna · May 11, 2025 · Facebook
  31. KETO-CTA: median non-calcified plaque volume rose 50% in one year Gokhan Can · May 08, 2025 · Facebook
  32. Keto-CTA figures suggest mean non-calcified plaque rise of 32.3 mm3, not the stated 18.8 Louis Nervegna · Apr 19, 2025 · Facebook
  33. KETO-CTA: why Louis thinks the flawed paper should stay published Louis Nervegna · May 30, 2025 · Facebook
  34. Mandrola critique: KETO-CTA did not upend the causal evidence for LDL in atherosclerosis Gokhan Can · May 31, 2025 · Facebook
  35. Range restriction may explain why ApoB showed no link to plaque progression in Keto-CTA Louis Nervegna · Apr 22, 2025 · Facebook
  36. Co-author of LMHR study protocol says the design could not detect plaque progression Louis Nervegna · Dec 10, 2023 · Facebook
  37. Budoff says Keto-CTA paper is being rewritten; JACC to issue a statement Louis Nervegna · Apr 18, 2025 · Facebook
  38. Budoff reportedly says Keto-CTA co-authors' claims about the primary outcome are wrong Louis Nervegna · Apr 18, 2025 · Facebook
  39. Three expert breakdowns of the KETO-CTA lean mass hyper-responder study Gokhan Can · Apr 15, 2025 · Facebook
  40. Quoted view: sky-high LDL on low-carb diets shows rapid plaque progression within a year Gokhan Can · Apr 14, 2025 · Facebook
  41. Stanford finds BHB-amino acids, a new keto metabolite family that suppresses appetite Gokhan Can · Nov 25, 2024 · Facebook
  42. Ketogenic diet associated with 67% vs 8% three-year survival in a tiny glioblastoma study Louis Nervegna · Mar 02, 2025 · Facebook
  43. Keto beat Mediterranean and low-fat diets on liver fat and glycemia at equal weight loss Gokhan Can · Aug 27, 2026 · Facebook
  44. Low-carb diets are no better for fat loss than other diets when calories are matched Louis Nervegna · Feb 16, 2026 · Facebook
  45. Low-carb diets lose their diabetes advantage by 12 months, trials and meta-analyses show Gokhan Can · Nov 25, 2025 · Facebook
  46. An oral glucose tolerance test is the definitive check that diabetes is truly resolved Louis Nervegna · Jul 31, 2025 · Facebook
  47. Very low-carb diets rarely push A1C below 5 because of physiological insulin resistance Louis Nervegna · May 25, 2026 · Facebook
  48. Keto/Atkins diet raised methylglyoxal 1.67-fold in 2-4 weeks, a glycation precursor Louis Nervegna · Sep 23, 2024 · Facebook
  49. Prolonged very low carb diets can suppress thyroid hormones while TSH looks normal Louis Nervegna · Oct 13, 2025 · Facebook
  50. Strict keto can suppress thyroid function (low T3, T4 and TSH); try adding back carbs Louis Nervegna · Nov 21, 2023 · Facebook
  51. Long-term keto in mice caused high cholesterol, fatty liver and poor insulin secretion Louis Nervegna · Oct 04, 2025 · Facebook
  52. No long-lived population ate a carbohydrate-free diet; long-term effects unknown Louis Nervegna · Jun 09, 2026 · Facebook
  53. Why a cross-sectional NHANES keto mortality study sits low on the evidence hierarchy Louis Nervegna · Jan 24, 2025 · Facebook
  54. Case report: rapid CAD progression after stopping statin and starting keto (LMHR) Louis Nervegna · Oct 28, 2024 · Facebook
  55. Keto-CTA: metabolic health and large LDL particles gave no protection from plaque Louis Nervegna · Aug 18, 2025 · Facebook
  56. Another carnivore influencer reports worsening cardiovascular health and plaque growth Louis Nervegna · Oct 21, 2025 · Facebook
  57. Favorite Mediterranean plus low-carb foods: a discussion thread Gokhan Can · Nov 30, 2023 · Facebook
  58. Louis calls out keto influencer claims about the Keto-CTA study Louis Nervegna · Jun 22, 2025 · Facebook

Keep exploring

Related research summaries

Topics and hashtags in this summary